Kid Cards: Teaching Kids About Medicines
NCT00127543 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2021-01-05
Summary
This study is being done to see if education about medicines directed toward children will improve their knowledge. The investigators also want to know if this knowledge lasts over time. Right now there are few medication instructional cards that are appropriate for children. Most of the medication cards provide information for adults. Some studies have shown that by teaching children directly, the children may take medicine at the right time for the right reason, have fewer side effects and know more about their medicine.
The purpose of this research study is to see if education about medication helps children learn more about their medicine and if this knowledge lasts.
Conditions
- Hemophilia
- Sickle Cell Disease
- Neoplasms
- Blood Coagulation Disorders
Interventions
- BEHAVIORAL
-
Medication Education for Children
Sponsors & Collaborators
-
Children's Mercy Hospital Kansas City
lead OTHER
Principal Investigators
-
Heather E Curry, RN, MSN · Childrens Mercy Hospitals and Clinics
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 7 Years
- Max Age
- 11 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-08-31
- Completion
- 2006-04-30
Countries
- United States
Study Locations
More Related Trials
-
Improving Disease Knowledge in Adolescents With Sickle Cell Disease
NCT01945073 ·Status: COMPLETED ·Phase: NA
-
Families Taking Control (FTC): Family-based Problem-solving Intervention for Children With Sickle Cell Disease
NCT02273310 ·Status: COMPLETED ·Phase: NA
-
Oral Health Status and Oral Health Related Quality of Life in a Group pf Egyptian Hemophilic Children
NCT07161596 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
NCT00389935 ·Status: COMPLETED ·Phase: PHASE2
-
Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease
NCT00459225 ·Status: WITHDRAWN ·Phase: NA
-
Curative Versus Disease-Modifying Therapies in Children With Severe Sickle Cell Disease
NCT01369160 ·Status: COMPLETED
-
Stroke Prevention in Sickle Cell Anemia (STOP 1)
NCT00000592 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Evaluation of a Motivational Interviewing Intervention Targeting Adherence Behaviors in Youth With Sickle Cell Disease
NCT04877054 ·Status: COMPLETED ·Phase: NA
-
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
NCT03587272 ·Status: RECRUITING ·Phase: PHASE2
-
Vascular Function Intervention Trial in Sickle Cell Disease
NCT01718054 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease
NCT02214121 ·Status: COMPLETED ·Phase: PHASE2
-
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
NCT00895154 ·Status: COMPLETED ·Phase: NA
-
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
NCT04688411 ·Status: RECRUITING ·Phase: NA
-
Parent Educational Program for Children With Sickle Cell Disease
NCT00860782 ·Status: COMPLETED ·Phase: NA
-
CHOICES3: Sickle Cell Disease Parenting CHOICES
NCT05292781 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
NCT00005934 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease
NCT00305175 ·Status: COMPLETED
-
The Use of Warmed Saline in Vaso-occlusive Episodes
NCT02316366 ·Status: COMPLETED ·Phase: NA
-
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
NCT02447874 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
NCT01506544 ·Status: COMPLETED ·Phase: PHASE1
-
Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
NCT03020615 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease
NCT01428154 ·Status: WITHDRAWN ·Phase: PHASE1
-
Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders
NCT04416178 ·Status: RECRUITING
-
A Study of HQK-1001 in Patients With Sickle Cell Disease
NCT01322269 ·Status: COMPLETED ·Phase: PHASE2
-
L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity
NCT05470998 ·Status: COMPLETED ·Phase: PHASE3